Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

  • Revenue in GBP (TTM)40.95bn
  • Net income in GBP5.79bn
  • Incorporated1992
  • Employees94.30k
  • Location
    AstraZeneca PLC1 Francis Crick AvenueCambridge Biomedical CampusCAMBRIDGE CB2 0AAUnited KingdomGBR
  • Phone+44 207 304 5000
  • Fax+44 207 604 8151
  • Websitehttps://www.astrazeneca.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AZN:LSE since
announced
Transaction
value
Esobiotec SrlDeal completed17 Mar 202517 Mar 2025Deal completed-12.49%1.00bn
Data delayed at least 20 minutes, as of Jul 15 2025 15:28 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sanofi SA39.23bn5.40bn89.10bn84.59k16.821.4113.142.274.975.0336.1459.09------533,959.10--6.12--7.5470.9469.2313.5917.970.68826.880.220559.376.413.318.5714.0012.324.47
Vertex Pharmaceuticals Inc8.27bn-736.44m90.33bn6.10k--7.36--10.93-3.88-3.8842.8664.200.47441.436.171,819,623.00-4.2314.06-5.0416.6786.0387.35-8.9126.282.29--0.00670.0011.6621.50-114.80--45.11--
Gilead Sciences Inc21.40bn4.44bn103.84bn17.60k23.717.2815.964.854.734.7322.7915.390.50983.456.351,632,671.0010.585.2613.636.3878.2978.4720.7612.541.237.800.5667108.476.045.08-91.53-38.34-8.714.10
Pfizer Inc46.52bn5.86bn107.33bn81.00k18.391.609.742.311.381.3810.9515.890.29111.465.47771,148.103.687.454.499.4374.5769.1012.6420.370.960412.260.406664.226.849.10275.82-5.272.323.13
Amgen Inc25.41bn4.42bn118.94bn28.00k27.1125.7313.854.6810.9610.9663.0511.540.37431.594.581,218,786.006.518.438.5010.6664.0772.8117.3921.900.8787.060.902471.3718.577.43-39.11-12.2112.149.18
Merck & Co Inc47.60bn12.98bn156.46bn75.00k12.184.369.503.296.876.8725.1919.210.57862.315.77852,293.3015.799.5220.4612.6477.0773.4727.3017.871.1623.900.418672.966.7410.404,589.5924.64-0.58856.66
AstraZeneca plc40.95bn5.79bn166.22bn94.30k28.925.4417.334.063.713.7126.2119.710.52731.734.52434,241.207.464.3210.355.9582.3680.2214.159.390.695410.420.4348107.6818.0317.2718.1439.4313.271.20
Novo Nordisk A/S35.28bn12.18bn174.89bn77.41k18.8814.2012.634.9623.4823.4868.0331.210.76931.244.793,972,910.0026.5527.7254.1555.7484.3384.2534.5134.120.557147.340.461550.1125.0318.9420.6820.9935.5022.25
Novartis AG39.60bn9.57bn190.42bn75.88k18.966.1813.524.815.095.0921.0515.620.54752.246.47559,044.2013.249.8019.3113.0875.6673.7624.1824.420.609717.410.447866.4210.851.2439.3710.8311.064.83
Roche Holding AG56.47bn7.73bn196.61bn103.25k24.976.4516.703.4810.3210.3275.4339.940.62932.065.42585,913.709.5614.4813.9122.5173.9171.9715.1921.431.2015.670.489464.023.03-0.318-28.01-9.320.45741.51
Data as of Jul 15 2025. Currency figures normalised to AstraZeneca PLC's reporting currency: UK Pound GBX

Institutional shareholders

20.64%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 31 Dec 202465.12m4.20%
BlackRock Investment Management (UK) Ltd.as of 31 Mar 202555.81m3.60%
The Vanguard Group, Inc.as of 01 Jul 202546.02m2.97%
BlackRock Fund Advisorsas of 01 Jul 202530.80m1.99%
Norges Bank Investment Managementas of 01 Jul 202530.47m1.97%
Capital Research & Management Co. (World Investors)as of 10 Mar 202526.97m1.74%
SSgA Funds Management, Inc.as of 01 Jul 202516.76m1.08%
Capital Research & Management Co. (Global Investors)as of 01 Jul 202516.25m1.05%
BlackRock Advisors LLCas of 01 Jul 202516.07m1.04%
Goldman Sachs Asset Management LPas of 01 Jul 202515.73m1.01%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.